Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for postoperative cognitive function and sleep after gastrointestinal surgery in critically ill patients
ChiCTR2300075153Phase 4Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in Postoperative sleep disturbance (PSD) and post-operative cognitive decline (POCD) (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Change in postoperative sleep cycle N2 phase. Started Aug 2023; status: recruiting.
02
Drugs
esketamine
03
Conditions
Postoperative sleep disturbance (PSD)post-operative cognitive decline (POCD)
Beyond the preview
Go deeper on ChiCTR2300075153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075153.